Salim Syed
Stock Analyst at Mizuho
(2.36)
# 2,590
Out of 5,113 analysts
77
Total ratings
45.16%
Success rate
0.85%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Salim Syed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INCY Incyte | Upgrades: Outperform | $90 → $121 | $103.47 | +16.94% | 1 | Dec 8, 2025 | |
| ASMB Assembly Biosciences | Maintains: Outperform | $29 → $40 | $27.52 | +45.35% | 2 | Nov 20, 2025 | |
| NKTX Nkarta | Maintains: Outperform | $16 → $14 | $2.54 | +451.18% | 8 | Jun 10, 2025 | |
| CYTK Cytokinetics | Maintains: Outperform | $103 → $84 | $64.01 | +31.23% | 7 | May 29, 2025 | |
| BIIB Biogen | Maintains: Outperform | $207 → $169 | $174.12 | -2.94% | 16 | May 7, 2025 | |
| AMGN Amgen | Maintains: Neutral | $235 → $280 | $351.32 | -20.30% | 8 | May 7, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $100 → $117 | $140.97 | -17.00% | 7 | May 5, 2025 | |
| WVE Wave Life Sciences | Maintains: Outperform | $19 → $22 | $13.36 | +64.67% | 5 | Nov 21, 2024 | |
| PCVX Vaxcyte | Maintains: Outperform | $113 → $163 | $54.35 | +199.91% | 3 | Sep 10, 2024 | |
| ATRA Atara Biotherapeutics | Upgrades: Outperform | $25 → $18 | $5.56 | +223.74% | 4 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $26.16 | +29.97% | 1 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $82 → $99 | $54.26 | +82.45% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $53 | $77.87 | -31.94% | 7 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $21 | $2.51 | +736.65% | 5 | Nov 16, 2022 |
Incyte
Dec 8, 2025
Upgrades: Outperform
Price Target: $90 → $121
Current: $103.47
Upside: +16.94%
Assembly Biosciences
Nov 20, 2025
Maintains: Outperform
Price Target: $29 → $40
Current: $27.52
Upside: +45.35%
Nkarta
Jun 10, 2025
Maintains: Outperform
Price Target: $16 → $14
Current: $2.54
Upside: +451.18%
Cytokinetics
May 29, 2025
Maintains: Outperform
Price Target: $103 → $84
Current: $64.01
Upside: +31.23%
Biogen
May 7, 2025
Maintains: Outperform
Price Target: $207 → $169
Current: $174.12
Upside: -2.94%
Amgen
May 7, 2025
Maintains: Neutral
Price Target: $235 → $280
Current: $351.32
Upside: -20.30%
Gilead Sciences
May 5, 2025
Maintains: Outperform
Price Target: $100 → $117
Current: $140.97
Upside: -17.00%
Wave Life Sciences
Nov 21, 2024
Maintains: Outperform
Price Target: $19 → $22
Current: $13.36
Upside: +64.67%
Vaxcyte
Sep 10, 2024
Maintains: Outperform
Price Target: $113 → $163
Current: $54.35
Upside: +199.91%
Atara Biotherapeutics
Aug 16, 2024
Upgrades: Outperform
Price Target: $25 → $18
Current: $5.56
Upside: +223.74%
Apr 9, 2024
Initiates: Buy
Price Target: $34
Current: $26.16
Upside: +29.97%
Mar 6, 2024
Maintains: Buy
Price Target: $82 → $99
Current: $54.26
Upside: +82.45%
Mar 5, 2024
Maintains: Buy
Price Target: $60 → $53
Current: $77.87
Upside: -31.94%
Nov 16, 2022
Maintains: Buy
Price Target: $28 → $21
Current: $2.51
Upside: +736.65%